International researchers have identified a new blood biomarker that could predict severe asthma attacks up to five years in advance, offering hope for more proactive and personalized management of the chronic respiratory disease.the study, published in Nature Communications, represents a notable step forward in a field where predicting exacerbations has historically been a challenge, potentially allowing clinicians to intervene before symptoms become life-threatening. Affecting over 500 million people globally, asthma’s unpredictable nature underscores the importance of this new predictive tool.
International study identifies blood biomarker that could predict severe asthma attacks up to five years in advance.
A simple blood test could revolutionize asthma management. An international team of researchers has developed a method capable of identifying patients at high risk of experiencing a severe asthma attack, potentially up to five years before it occurs. The groundbreaking findings, published in the journal Nature Communications, represent a significant step forward in managing a disease that affects more than 500 million people worldwide. Early identification of risk could allow for proactive intervention and improved patient outcomes.
Understanding Asthma and its Risks
Asthma is a chronic inflammatory disease that narrows the airways, making it difficult to breathe. Common symptoms include coughing, wheezing, chest tightness, and shortness of breath. According to the Mayo Clinic, the severity of asthma can range from mild discomfort to life-threatening episodes requiring emergency medical care.
Asthma attacks are often triggered by allergens, respiratory infections, exercise, or stress. While there is no cure for asthma, it can be effectively managed with treatment and ongoing medical monitoring. A major challenge has been accurately predicting who will experience a severe attack and when it might happen.
A Biomarker for Predicting Future Attacks
Currently, doctors rely on tools like pulmonary function tests and blood eosinophil counts to assess asthma control. These evaluations provide a snapshot of a patient’s current condition but lack the ability to reliably predict future episodes.
The new research identified a biomarker based on the relationship between two types of molecules in the blood: sphingolipids and steroids. Measuring the balance between these molecules allows for the prediction of asthma exacerbations, even several years in advance.
Study Details and Accuracy
The analysis included blood samples and medical records from over 2,500 adults with asthma, drawn from three large international cohorts. Researchers utilized metabolomics – a technique that detects small molecules involved in cellular metabolism – to identify patterns not visible with conventional studies.
Investigators from Mass General Brigham and the Karolinska Institutet discovered that the ratio of sphingolipids to steroids accurately predicted which patients would suffer an asthma attack with nearly 90% accuracy. The predictive model was validated across different groups and consistently yielded strong results.
“The interaction between sphingolipids and steroids determines the risk profile,” explained Craig Wheelock, of the Karolinska Institutet. “This approach not only makes biological sense, it is also robust and suitable for becoming a practical and affordable clinical test.”
Advantages Over Traditional Assessments
The new model’s performance significantly surpassed current tools. The measurement achieved an “area under the curve” value of 0.90, compared to a range of 0.50 to 0.70 for standard clinical evaluations.
Furthermore, the system was able to anticipate the timing of the first attack. Patients classified as high-risk experienced their first exacerbation more than 100 days before those considered low-risk, opening the possibility for earlier intervention.
Potential Impact on Asthma Treatment
According to Jessica Lasky-Su, a researcher at Mass General Brigham, the advance addresses a long-standing need. “One of the biggest challenges in asthma treatment is that we don’t have an effective way to know who will have a severe attack in the near term. Our findings address this critical need,” she noted.
Predicting risk could allow for treatment adjustments before symptoms worsen and prevent long-term complications. The study also found that certain metabolites related to gut microbiota influence attacks, although the role of sphingolipids and steroids was most significant.
Next Steps Before Clinical Use
The team has filed a patent for the method but cautions that clinical trials and validation in more diverse populations are still needed. Researchers emphasize that the model could be implemented in standard laboratories, facilitating its adoption in everyday medical practice.
“The potential impact is enormous, as we could identify those who appear stable but have an underlying metabolic imbalance,” Wheelock stated.
The findings pave the way for more personalized asthma management and the possibility of reducing severe attacks before they occur.
